Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C-reactive protein. the Cardiovascular risk in young finns study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 2, 2009, Pages 168-174

  Haarala, Atte ^a   Eklund, Carita ^a   Pessi, Tanja ^a   Lehtimäki, Terho ^b   Huupponen, Risto ^c   Jula, Antti ^d   Viikari, Jorma ^e   Raitakari, Olli ^e   Hurme, Mikko ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TYKSLAB ^*  (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Body mass index; Haplotypes; Leptin; Progestins; Triglycerides

Indexed keywords

C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; CYPROTERONE; GESTAGEN; LEPTIN; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; METABOLISM; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; BLOOD; CARDIOVASCULAR DISEASE; FINLAND; GENETICS; MULTIVARIATE ANALYSIS; RISK FACTOR;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-SECTIONAL STUDIES; FINLAND; HUMANS; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 65649111273     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802449642     Document Type: Article

References (34)

1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
2. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
3. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006;119:166 e117-28.
4. Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive rotein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006;106:291-7.
5. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004;50:130-4.
6. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007;50:1115-22.
7. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
8. Eklund C, Kivimaki M, Islam MS, Juonala M, Kahonen M, Marniemi J, et al. C-reactive protein genetics is associated with carotid artery compliance in men in The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2008;196:841-8.
9. Kivimaki M, Lawlor DA, Smith GD, Eklund C, Hurme M, Lehtimaki T, et al. Variants in the CRP gene as a measure of lifelong differences in average C-reactive protein levels: the Cardiovascular Risk in Young Finns Study, 1980-2001. Am J Epidemiol 2007;166:760-4.
10. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345: 1787-93.
11. Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol 2007;14:488-93.
12. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT. Distribution and determinants of serum highsensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 2005;258:428-34.
13. Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969-77.
14. Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Proinflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol 2002;39:149-54.
15. Buchbinder S, Kratzsch J, Fiedler GM, Yar V, Brugel M, Leichtle A, et al. Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 2008;68:140-4.
16. Akerblom HK, Viikari J, Uhari M, Rasanen L, Byckling T, Louhivuori K, et al. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the crosssectional study of 1980, and an account of the children's and families' state of health. Acta Paediatr Scand Suppl 1985; 318:49-63.
17. Juonala M, Viikari JS, Hutri-Kahonen N, Pietikainen M, Jokinen E, Taittonen L, et al. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. J Intern Med 2004;255:457-68.
18. Viikari LA, Huupponen RK, Viikari JS, Marniemi J, Eklund C, Hurme M, et al. Relationship between leptin and C-reactive protein in young Finnish adults. J Clin Endocrinol Metab 2007;92:4753-8.
19. Telama R, Yang X, Viikari J, Valimaki I, Wanne O, Raitakari O. Physical activity from childhood to adulthood: a 21-year tracking study. Am J Prev Med 2005;28:267-73.
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
21. Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 2007;75:430-7.
22. Taskinen S, Kovanen PT, Jarva H, Meri S, Pentikainen MO. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 2002;367:403-12.
23. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7.
24. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
25. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-19.
26. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-67.
27. Godsland IF. Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 2004;47:299-303.
28. Williams MJ, Williams SM, Milne BJ, Hancox RJ, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 2004;28: 998-1003.
29. van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006;4:77-82.
30. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. J Am Med Assoc 2002;288:980-7.
31. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-5.
32. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470-6.
33. Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995;102: 217-23.
34. Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999;194:6-11.